XORTX Therapeutics Inc. cash flow to debt ratio of -7.57K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

XORTX Therapeutics Inc.'s free cash flow has increased -19.56% from $-3.50M last year to $-2.82M, signaling increasing performance

XORTX Therapeutics Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

XORTX Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

XORTX Therapeutics Inc. has a net cash position, so leverage is healthy.

XORTX Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

XORTX Therapeutics Inc. has insufficient data to evaluate this check.

XORTX Therapeutics Inc.'s short-term assets of $965.53K exceed its short-term liabilities of $597.98K

XORTX Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

XORTX Therapeutics Inc.'s return on equity of -135.33%, is lower than 15.00%, indicating bad performance

XORTX Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

XORTX Therapeutics Inc. has insufficient public price history to evaluate earnings stability.

XORTX Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

XORTX Therapeutics Inc. has negative free cash flow, indicating cash burn

XORTX Therapeutics Inc.'s yearly earnings has increased -15.79% since last year from $-3.15M to $-2.66M, signaling increasing performance

XORTX Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -238.89% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

XORTX Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

XORTX Therapeutics Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

XORTX Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.

XORTX Therapeutics Inc. has insufficient data to evaluate this check.

XORTX Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

XORTX Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

XORTX Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

XORTX Therapeutics Inc. has insufficient data to evaluate this check.

XORTX Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

XORTX Therapeutics Inc. has a price-to-book ratio of 2.34x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

XORTX Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue